Cargando…

Improved and new-onset anemia during follow-up in patients with acute decompensated heart failure: Characteristics and outcomes

There was no previous report on the prognostic impact of new-onset or improved anemia after discharge from acute decompensated heart failure (ADHF). We analyzed 771 patients with ADHF and who were followed in multicenters in Japan was divided into 4 groups based on the hemoglobin values at discharge...

Descripción completa

Detalles Bibliográficos
Autores principales: Seko, Yuta, Kato, Takao, Morimoto, Takeshi, Yaku, Hidenori, Inuzuka, Yasutaka, Tamaki, Yodo, Ozasa, Neiko, Shiba, Masayuki, Yamamoto, Erika, Yoshikawa, Yusuke, Kitai, Takeshi, Yamashita, Yugo, Iguchi, Moritake, Nagao, Kazuya, Kawase, Yuichi, Morinaga, Takashi, Toyofuku, Mamoru, Furukawa, Yutaka, Ando, Kenji, Kadota, Kazushige, Sato, Yukihito, Kuwahara, Koichiro, Kimura, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360432/
https://www.ncbi.nlm.nih.gov/pubmed/34397913
http://dx.doi.org/10.1097/MD.0000000000026892
Descripción
Sumario:There was no previous report on the prognostic impact of new-onset or improved anemia after discharge from acute decompensated heart failure (ADHF). We analyzed 771 patients with ADHF and who were followed in multicenters in Japan was divided into 4 groups based on the hemoglobin values at discharge and 6-month index visit: 373 patients (48.4%) with persistent anemia, 87 patients (11.3%) with new-onset anemia, 91 patients (11.8%) with improved anemia, and 220 patients (28.5%) without anemia. The primary outcome measure was a composite of all-cause death or HF hospitalization after index visit. The cumulative 6-month incidences of the primary outcome measure were 25.2% for persistent anemia, 18.5% for new onset anemia, 9.0% for improved anemia, and 9.2% for no anemia (log-rank P < .001). Compared with the no anemia group, the excess risk for the primary outcome measure remained significant in the persistent anemia group [hazard ratio (HR) 2.70, 95% confidence interval (95% CI), 1.45–5.44, P = .001] and in the new-onset anemia group (HR 2.73, 95% CI 1.19–6.25, P = .02), while it was not significant in the improved anemia group (HR 1.69, 95% CI 0.68–4.03, P = .25). Persistent and new-onset anemia at 6-month visit were associated with a subsequent higher risk for all-cause death or HF hospitalization in patients with ADHF, suggesting the importance of detecting anemia during follow-up.